ClearSight Therapeutics Joins MassChallenge U.S. Early Stage Healthcare Program

ClearSight Therapeutics has been selected to join the 2025 U.S. Early Stage Healthcare Program by MassChallenge, a premier global startup accelerator supporting high-impact ventures across industries. This recognition places ClearSight among a competitive group of early-stage healthcare innovators tackling some of the world’s most pressing challenges.

As part of this year’s program, ClearSight will engage with a global community of startups and experts that will help them grow and scale.

Learn more